Ruxolitinib . phosphate salt [1092939-17-7]

Catalog number: AG-CR1-3645-M005
Brand: AdipoGen Life Sciences
Packing: 5 mg
Other sizes: Other sizes available
Price: € 45.00
Expected delivery time: 7 days
Quantity:
Chemical Structure
Chemical Structure...

Product specifications for - Ruxolitinib . phosphate salt [1092939-17-7]

Overview: 
Product group: Chemicals
Category: Inhibitors / activators
CAS No.: 1092939-17-7
Properties: 
Purity: >97% (HPLC)
Molecular Formula: C17H18N6 . H3O4P
Molecular weight: 306.4 . 98.0
Datasheet: Datasheet
  Research Use Only
UNSPSC: 51202000
Storage instructions: 2-¦C to 8-¦C, -20-¦C
Scientific information: 
Scientific info: Chemical. CAS: 1092939-17-7. Formula: C17H18N6 . H3O4P. MW: 306.4 . 98.0. Water-soluble phosphate salt of Ruxolitinib. Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. - Water-soluble phosphate salt of Ruxolitinib. Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro.
Safety information: 
MSDS: MSDS
Hazard information: Non-hazardous, Warning
Additional information: 
Synonyms: AG-CR1-3645-M005; AdipoGen Life Sciences
Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction: Q. Lin, et al.; Org. Lett. 11, 1999 (2009) Read more
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms: A. Quintas-Cardama, et al.; Blood 115, 3109 (2010) Read more
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050: J.S. Fridman, et al.; J. Immunol. 184, 5298 (2010) Read more
Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis: R.A. Mesa; IDrugs 13, 394 (2010) Read more
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo: A. Heine, et al.; Blood 122, 1192 (2013) Read more
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348): T. Zhou, et al.; Leukemia 28, 404 (2014) Read more
Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro: G.S. Wilson, et al.; Cancer Lett. 341, 224 (2013) Read more
INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells: H.J. An, et al.; Neoplasma 61, 56 (2014) Read more
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? A. Heine, et al.; Blood 122, 3843 (2013) Read more
Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro: C. Gavegnano, et al.; Antimicrob. Agents Chemother. 58, 1977 (2014) Read more